tag:blogger.com,1999:blog-7857054149675424609.post6634358829025188441..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Bristol-Myers Squibb Deal Further Positions Tekmira as RNAi Therapeutics Delivery HubDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger8125tag:blogger.com,1999:blog-7857054149675424609.post-53479814014974359142008-08-19T01:22:00.000+00:002008-08-19T01:22:00.000+00:00Martin- I will address the ApoB patent issue in my...Martin- I will address the ApoB patent issue in my next entry. ISIS certainly emphasized the "double-stranded antisense" (??) in the press release quite a bit.<BR/><BR/>Anonymous- Thanks for the interesting article. With regard to the application of RNAi Therapeutics, I do not think that it will complicate matters too much. Merck and others e.g. are well aware that many of the future RNAi Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-63917978746455529892008-08-18T04:14:00.000+00:002008-08-18T04:14:00.000+00:00http://www.nytimes.com/2007/07/01/business/yourmon...http://www.nytimes.com/2007/07/01/business/yourmoney/01frame.html?pagewanted=allAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-9750883346631268852008-08-16T20:18:00.000+00:002008-08-16T20:18:00.000+00:00Dirk, I have a question related to TKM's ApoB SANL...Dirk, I have a question related to TKM's ApoB SANLP program that you discuss above.<BR/><BR/>Recently, ISIS was issued a patent that ISIS claims is very broad and covers any ApoB targeting. Do you know if this patent also covers ApoB targeting through RNAi mechanism of action? If so, TKM will presumably have to go to ISIS for a license at some point.<BR/><BR/>MartinAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-25577825179058077912008-08-16T02:50:00.000+00:002008-08-16T02:50:00.000+00:00Martin- thank you for your perspectives. Just to ...Martin- thank you for your perspectives. Just to add to your observation that Tekmira's market potential is larger than it sometimes appears to be. Not only is Alnylam Tekmira's best marketing partner for RNAi Therapeutics, Tekmira's technology is also highly relevant to small molecule and large DNA delivery and this could be monetized on Tekmira's terms only.<BR/><BR/>As an investor in TekmiraDirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-59623532241069363242008-08-15T23:10:00.000+00:002008-08-15T23:10:00.000+00:00Derek is correct actually. It is 16M in milestone...Derek is correct actually. <BR/><BR/>It is 16M in milestones, out of which 4.5M are linked to pre-approval events and the balance due upon the 500M cummulative sales hurdle.<BR/><BR/>The royalties are mid-single digits and not subject to the 500M hurdle.<BR/><BR/>(see p. 40 of the prospectus)<BR/><BR/>I tend to agree that TKM does not get a very big piece of the pie here but the pie could Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-64653562792220988182008-08-15T22:03:00.000+00:002008-08-15T22:03:00.000+00:00You are right, it seems that TKM has limited strat...You are right, it seems that TKM has limited strategic options following the Alnylam deal. BUT, in return they got 3 exclusive and 4 non-exclusive target picks from Alnylam, the real crown jewels of the deal. Everything else serves to fund TKM's own pipeline efforts in the least dilutive way possible. <BR/><BR/>In addition to the undisclosed royalties, Tekmira also gets funding through their Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-474055393377924352008-08-15T19:43:00.000+00:002008-08-15T19:43:00.000+00:00Derek: Tekmira receives up to US$16.0 million in "...Derek: Tekmira receives up to US$16.0 million in "milestones" on each and every RNAi therapeutic advanced by Alnylam or its partners that utilizes the TKM's technology. Tekmira also gets royalties on product sales, with the $500 million hurdle you mention applying to royalties not milestones. So, assuming multiple drugs using SNALP get FDA approval, the potential payoff to Tekmira is enormous. MyAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-26199458874541313182008-08-15T15:53:00.000+00:002008-08-15T15:53:00.000+00:00Dirk,I agree that Tekmira seems to be getting the ...Dirk,<BR/><BR/>I agree that Tekmira seems to be getting the most traction becoming an RNAi delivery hub. However, they only get a very small piece of the pie if and when any SNALP RNAi therapeutics are delivered. If I read correctly, I believe they get a maximum amount of $16MM per therapeutic (and that is only if cumulative sales break $500MM). It will take a lot of successful therapeutics for Anonymousnoreply@blogger.com